Soligenix's Upcoming Catalysts Highlight Growth Potential as it Sheds Light on its Commercialization of SGX301
New York, New York--(Newsfile Corp. - February 9, 2021) - PCG Digital: Soligenix (NASDAQ: SNGX) continues to build excitement for its SGX301 candidate following strong Phase 3 data and commercialization plans. The company recently held an investor webcast to further explain the company's plans for commercializing its ground-breaking SGX301 candidate for the treatment of cutaneous T-cell lymphoma (CTCL). Here are some key takeaways from the commercialization Q&A: 1. Soligenix will...
2021-02-09 8:30 AM EST
U.S. Patent Follows Key Advisory Board Additions-What's Next for Bubblr?
New York, New York--(Newsfile Corp. - February 9, 2021) - PCG Digital - 2021 has already been a big year for ethical technology company Bubblr (OTC Pink: BBLR). After going public and expanding its advisory board with notable industry experts in late 2020, Bubblr received a Notice of Allowance from the U.S. Patent and Trademark Office for a utility patent application for its Internet-based Search Mechanism. This patent will help users interact and search anonymously with providers of goods...
2021-02-09 8:30 AM EST
Soligenix Poised to Announce US Commercialization Plans of SGX301 in the Treatment of Cutaneous T-Cell Lymphoma
New York, New York--(Newsfile Corp. - January 25, 2021) - PCG Digital: Advancing health care innovation is a cornerstone of thorough public health policy. Researching and developing new treatments for unmet medical needs has become increasingly important as the world continues to battle through the worst pandemic in our lifetime. While the news and focus of health innovation continues to be largely on COVID-19, medical breakthroughs continue to progress across the board.Soligenix, Inc....
2021-01-25 8:30 AM EST
Soligenix, Inc. COVID-19 Vaccine Candidate, CiVax, Could Be a More Viable Alternative to Moderna and Pfizer
New York, New York--(Newsfile Corp. - December 9, 2020) - The COVID-19 pandemic has been one of the most significant "black swan" events in recent history. As of early December 2020, around 1.5 million people globally have died from the coronavirus, including over 274,000 deaths in the United States. At the same time, millions of people have lost their jobs, businesses, and other income sources. The only way to truly recover from this pandemic is from widespread vaccination and continued...
2020-12-09 8:30 AM EST
Pfizer and Moderna COVID-19 Vaccine Candidates Are Promising, but Soligenix's Civax (TM) May Be a Better Alternative
New York, New York--(Newsfile Corp. - November 17, 2020) - Enthusiasm is surrounding Pfizer's and Moderna's announcement of COVID-19 vaccine candidates that may soon become ripe for approval. But, in all fairness to the progress, tempering some of the excitement is warranted. There are two significant concerns. First, both Pfizer and Moderna candidates use synthetic mRNA technology to activate the immune system against the virus and must be kept at minus 70 degrees Celsius (-94 F) or below,...
2020-11-17 8:00 AM EST
With FDA and EU Marketing Authorizations in Hand, 2020 and 2021 Can Be Catalyst Years for Arch Therapeutics
New York, New York--(Newsfile Corp. - September 22, 2020) - Arch Therapeutics, Inc. (OTCQB: ARTH) has cleared significant hurdles to commercialize its AC5 Advanced Wound System and AC5 Topical Hemostat.1 In particular, two events position the company to create substantial value-creation by turning milestones into catalysts.The first event happened in March of this year with the U.S. Food and Drug Administration (FDA) providing clearance to market its novel AC5 Advanced Wound System, which is...
2020-09-22 8:30 AM EDT
Soligenix's RiVax(R) Program Back in Focus After Deadly Ricin Toxin Intercepted Before Reaching White House
New York, New York--(Newsfile Corp. - September 21, 2020) - Soligenix's (NASDAQ: SNGX) RiVax® program is in focus after a failed attempt to send ricin-laced letters to the White House last week raised fresh concerns about the deadly toxin. Those letters, including others addressed to Texas law enforcement agencies, were intercepted before delivery on Thursday. That news helped focus attention toward Soligenix's RiVax® program, which is considered the leading ricin-poisoning vaccine program in...
2020-09-21 8:30 AM EDT
PCG Research Announces Publication of Update Report Covering Zomedica Pharmaceuticals Corp.
New York, New York--(Newsfile Corp. - June 25, 2020) - PCG Research, the equity research division of PCG Advisory, Inc., a leading investor relations and strategic advisory firm based in New York City focused on small and micro-cap public companies, today announced it has published an updated research report on Zomedica Pharmaceuticals, Corp. (NYSE American: ZOM).The report is available here.
2020-06-25 9:26 AM EDT
PCG Research Announces Publication of Report Covering MasterMind, Inc.
New York, New York--(Newsfile Corp. - March 24, 2020) - PCG Research, the equity research division of PCG Advisory, Inc., a leading investor relations and strategic advisory firm based in New York City and focused on small and micro-cap public companies, today announced it has initiated coverage on MasterMind, Inc. (OTCQB: MMND)The report is available here: http://get.ceo3in60.com/mmnd-report/"MasterMind is a leading digital marketing company that helps its Fortune 500 clients build brand...
2020-03-24 4:05 PM EDT
PCG Research Announces Publication of Report Covering Zomedica Pharmaceuticals Corp.
New York, New York--(Newsfile Corp. - September 11, 2019) - PCG Research, the equity research division of PCG Advisory, Inc., a leading investor relations and strategic advisory firm based in New York City and focused on small and micro-cap public companies, today announced it has initiated coverage on Zomedica Pharmaceuticals, Corp. (NYSE: ZOM) PCG Research, the equity research division of PCG Advisory, Inc.
2019-09-11 9:09 AM EDT